130 related articles for article (PubMed ID: 17721682)
1. Relationship between the initial dose of micafungin and its efficacy in patients with candidemia.
Ota Y; Tatsuno K; Okugawa S; Yanagimoto S; Kitazawa T; Fukushima A; Tsukada K; Koike K
J Infect Chemother; 2007 Aug; 13(4):208-12. PubMed ID: 17721682
[TBL] [Abstract][Full Text] [Related]
2. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
[TBL] [Abstract][Full Text] [Related]
3. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.
Natarajan G; Lulic-Botica M; Aranda JV
J Perinatol; 2009 Nov; 29(11):738-43. PubMed ID: 19776753
[TBL] [Abstract][Full Text] [Related]
4. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.
Ostrosky-Zeichner L; Kontoyiannis D; Raffalli J; Mullane KM; Vazquez J; Anaissie EJ; Lipton J; Jacobs P; van Rensburg JH; Rex JH; Lau W; Facklam D; Buell DN
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):654-61. PubMed ID: 16261306
[TBL] [Abstract][Full Text] [Related]
5. [A successful treatment with micafungin of candidemia due to Candida krusei].
Nonoyama M; Kume H; Kumagai K; Souma K; Sunakawa K
Kansenshogaku Zasshi; 2003 Nov; 77(11):982-5. PubMed ID: 14672012
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Gumbo T; Drusano GL; Liu W; Kulawy RW; Fregeau C; Hsu V; Louie A
Antimicrob Agents Chemother; 2007 Mar; 51(3):968-74. PubMed ID: 17194830
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between the effectiveness and dose of micafungin in the treatment of candidemia].
Sugawara T; Murakami N; Uetake N; Matsumoto S; Miyamori S; Okamoto R; Hiraki K
Yakugaku Zasshi; 2014; 134(3):433-8. PubMed ID: 24584025
[TBL] [Abstract][Full Text] [Related]
8. [Successful treatment with micafungin in a case of candidemia associated with pneumonia].
Hanada M; Imaoka H; Oshita Y; Rikimaru T; Aizawa H
Kansenshogaku Zasshi; 2005 Apr; 79(4):284-9. PubMed ID: 15977567
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis associated with micafungin use in a preterm infant.
King KY; Edwards MS; Word BM
J Perinatol; 2009 Apr; 29(4):320-2. PubMed ID: 19325554
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.
Pettengell K; Mynhardt J; Kluyts T; Lau W; Facklam D; Buell D;
Aliment Pharmacol Ther; 2004 Aug; 20(4):475-81. PubMed ID: 15298643
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.
Kohno S; Masaoka T; Yamaguchi H; Mori T; Urabe A; Ito A; Niki Y; Ikemoto H
Scand J Infect Dis; 2004; 36(5):372-9. PubMed ID: 15287383
[TBL] [Abstract][Full Text] [Related]
13. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.
Horn DL; Ostrosky-Zeichner L; Morris MI; Ullmann AJ; Wu C; Buell DN; Kovanda LL; Cornely OA
Eur J Clin Microbiol Infect Dis; 2010 Feb; 29(2):223-9. PubMed ID: 20013016
[TBL] [Abstract][Full Text] [Related]
14. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
[TBL] [Abstract][Full Text] [Related]
15. [Micafungin for therapy of invasive candidiasis in solid organ transplant recipients].
Fortún-Abete J
Rev Iberoam Micol; 2009 Mar; 26(1):65-8. PubMed ID: 19463280
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of micafungin for the treatment of candidemia.
Andes D; Safdar N
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):662-4. PubMed ID: 16247615
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China.
Chen D; Wan X; Kruger E; Chen C; Yue X; Wang L; Wu J
J Med Econ; 2018 Mar; 21(3):301-307. PubMed ID: 29303621
[TBL] [Abstract][Full Text] [Related]
18. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection.
Kludze-Forson M; Eschenauer GA; Kubin CJ; Della-Latta P; Lam SW
Med Mycol; 2010 Mar; 48(2):436-9. PubMed ID: 20141378
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
